ArcherDx has appointed Steven Kafka as executive chairman of its board of directors. Kafka will replace Kyle Lefkoff, founder and general partner of Boulder Ventures. Lefkoff will remain on the board of ArcherDx. Kafka currently serves as a partner at Third Rock Ventures. Prior to Third Rock Ventures, Kafka served as president and chief operating officer at Foundation Medicine. Prior to Foundation, Kafka held executive roles at several public and private oncology drug discovery and development companies.
Kevin Conroy, Michelle Griffin
Adaptive Biotechnologies has appointed Kevin Conroy and Michelle Griffin to its board of directors. Board member Arnold Levine has transitioned to the firm's scientific advisory board.
Conroy currently serves as CEO and chairman of Exact Sciences. He has also served as president of Exact Sciences. Prior to joining Exact Sciences, Conroy served as president and CEO of Third Wave Technologies from 2005 to 2008.
Griffin currently serves as a board of director member and audit committee chair for Acer Therapeutics and HTG Molecular Diagnostics. Griffin previously served on the board of directors and audit committee chair for PhaseRx from 2016 to 2018, OncoGenex Pharmaceutics from 2008 to 2011, and Sonus Pharmaceuticals from 2004 to 2008. She has also served as executive VP of operations and chief financial officer at OncoGenex from 2011 to 2013. She also held the positions of CEO, senior VP, and chief operating officer at Trubion Pharmaceuticals from 2009 to 2010, and acted as the firm's CFO from 2006 from 2009. Griffin also served as senior VP and CFO of Dendreon from 2005 to 2006.
Padma Sundar, Kim Dickinson
OncoCyte has appointed Padma Sundar as its senior VP of marketing and market access. The firm has also appointed Kim Dickinson as its VP of clinical operations.
Prior to OncoCyte, Sundar served as VP of strategy and market access at CellMax Life. Before CellMax, she acted as director of marketing at Guardant Health. Prior to Guardant, Sundar served as senior director at Roche Sequencing. She also held the role of senior director for Affymetrix's oncology portfolio.
Before OncoCyte, Dickinson served as VP of research and development and chief pathologist at Biocare Medical. Prior to BioCare, she served as VP of clinical operations at Roche Tissue Diagnostics. She also served as medical director for Laboratory Corporation of America' clinical trials division. Before working at LabCorp, Dickinson acted as medical director at Esoteric Testing. Prior to Esoteric, Dickinson worked at Quest Diagnostics, Citrus Valley Medical Center, and Pioneer Hospital.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.